April 15th, 2008
Kythera Biopharmaceuticals Announces Second Phase II Clinical Trial With Adipolytic Agent For Reduction Of Submental Fat
Kythera Biopharmaceuticals, Inc. ("Kythera") announced the initiation of a second Phase II clinical trial evaluating its proprietary product, ATX-101, for the reduction of unwanted submental (under chin) fat. This clinical trial is the second in a series of Phase II studies of ATX-101 in aesthetic applications and is aimed at assessing the safety and effectiveness of ATX-101 as a "liposculpting" agent.
Pages
Archives
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
- August 2007
- July 2007
- June 2007
- May 2007
- April 2007
- February 2007
- January 2007
- December 2006
- October 2006
- September 2006
- December 1969
Categories
- (1)
- (1)
- Breast Implants (2)
- Plastic Surgeons (260)
- Plastic Surgery (1)
- Uncategorized (92)